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rs121918398Abstract Genetic susceptibility, is considered to be involved in neurodegenerative diseases such as
Alzheimer’s disease (AD) and Parkinson’s disease (PD). Despite the fact that many susceptibility
genes for AD and PD have been considered, the most probable genetic risk factor which has been
taken into consideration is Apolipoprotein E genotype located on chromosome 19q, APOE is the
gene widely considered to be a susceptibility gene for neurodegenerative diseases. This study is to
investigate the association of APOE polymorphism with AD and PD. In this case control study
we examined association of an APOE gene polymorphism (rs121918398) with AD and PD in Iranian
population. The study included 100 AD patients, 100 PD patients and 150 healthy volunteers. An
informed consent was obtained from all participants. Genomic DNA was extracted from peripheral
blood leukocyte. Genotypes were determined by PCR and restriction fragment length polymorphism
(RFLP) by Hha1 restriction enzyme. Sequencing of PCR products was carried out by Fazabiotech
Company according to Sanger method using ABI 3730XL Capillary Sequencer. Statistical analysis
was performed using the MedCalc program. The prevalence of genotype frequencies of the APOE
A/A, A/G, G/G were 16%, 34% and 50% in AD subjects, 14%, 32%, 54% in PD patients and in
healthy volunteers were 15%, 39% and 96% respectively. Statistical analysis showed no significant
difference between genotype frequencies of AD and those of control subjects (P< 0.05). Moreover,
according to statistical analysis, the genotype frequencies of APOE in PD subjects and control group
did not significantly differ. This is the very first time that the association of this polymorphism
(rs121918398) with AD is being reported nevertheless, there is no evidence that APOE variant is
associated with PD. Accordingly, genotype alteration of A8390>G can’t be related to AD. So, this
polymorphism plays no pathogenic role in the PD and AD patients in Iranian population.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Dementia is the progressive decline in cognitive function due
to damage of the brain, and is different from the slowing of
cognitive function that is expected with normal aging [1]. Life
expectancy has increased in last decades and health care
improvements have contributed to people living longer. How-
ever, this has also contributed to increase in the number of
people with chronic disabling diseases such as Alzheimer
(AD) and Parkinson (PD). Several endogenous (genetic) and
exogenous (environmental) factors contribute to the onset
and/or development of these illnesses [2]. AD, the main form
of dementia in aged people, is thought to account for 60–
70% of cases. It is progressive, disabling and irreversible [3].
Clinic-wise, this disease is defined by progressive wane in mem-
ory, language, administrative function and other cognitional
functions [4]. Progressive brain atrophy is observed in AD,
with an inflammatory response of astrocytes and neurons, as
well as deposition of neurofibrillary tangles (NFT) and amy-
loid plaques [5]. PD, the second most common neurodegener-
ative disorder after AD, is a chronic and progressive
neurological disease, in which selective loss of dopaminergic
neurons of the substantia nigra pars compacta (SNpc) is seen
[6]. In addition to the neuronal loss, the existence of Lewy bod-
ies (LB), in the surviving neurons, is the main neuropatholog-
ical characteristic of PD, [7]. AD and PD have some clinical
and neuropathological features in common [8].
In the central nervous system (CNS), glial cells produce
APOE, and present it in high-density-like lipoproteins. APOE,
binding to the amyloid-b (Ab) peptide, interacts with different
receptors which are members of the low-density lipoprotein
receptor (LDLR) family [9]. In some neurons, in the case of
brain injury, APOE levels increase drastically. This can affect
neurite extension, Thus it is thought to play a key role in the
protection and repair of neurons [10].
The genes APOE2, APOE3 and APOE4 (Three common
isoforms of the protein) which are located within the APOE
gene on chromosome 19, account for more than 99% of the
variation of APOE [11]. Single nucleotide polymorphisms
(SNPs), genetic variants that cause a difference in a single base
pair in DNA, may lead to changes in a protein which might be
important in a disease specific pathway [12]. SNPs are the most
occurring polymorphisms of DNA sequence variations [13].
The human APOE gene contains many SNPs, spread across
the gene [14]. The three most common SNPs resulting in
changes in the coding sequence include: APOE2 (cys112,
cys158), APOE3 (cys112, arg158), and APOE4 (arg112,
arg158) [15].
Although there have been many worldwide efforts on find-
ing a relationship between APOE alleles and neurodegenera-
tive disease, yet no report has been made on these SNPs [16],
therefore, in this study, we investigated a polymorphism of
APOE gene (8390G>A) and its association with AD and
PD for the first time, which has been introduced as
rs121918398. This polymorphism (APOE4) is pathogenic
[13]. To our knowledge, so far, no study has been done on
the effect of R292H mutation (rs121918398) on AD and PD
development. So here we present the results of the investiga-
tion of association of this polymorphism with AD and PD
and determine the prevalence of R292H mutation in Iranian
population.2. Subjects and methods
2.1. Study subject
In this case control study, 100 patients suffering from con-
firmed AD (74 females and 26 males), and 100 PD patients
(46 females and 54 males) with the minimum age of 60 (mean
78.96 ± 10.99) were enrolled. The controls included 150
healthy people (93 females and 57 males) with the same ages
(mean 77 ± 10.66). The sample selection was done randomly,
whereas we know that the prevalence of neurodegenerative dis-
ease in females is more than males [17]. None of the controls
had a clinical history of neurological diseases or had taken
any drug related to nervous disorders. All donors gave their
informed written consent prior to participation and completed
a written questionnaire to give information related to their
family history and ethnicity. The work has been carried out
in accordance with The Code of Ethics of the World Medical
Association (declaration of Helsinki) for experiments in
humans that is approved by the local ethics committee of Gui-
lan University. The predominant ethnic background of all
groups were Iranian.
2.2. DNA extraction
DNA was extracted from peripheral blood lymphocytes using
the Salting out DNA extraction method [18] and quality was
confirmed on agarose gel 1%. All reactions were optimized
to give clean ample quantities of DNA.
2.3. Polymerase chain reaction (PCR)
Amplification of a fragment containing this SNP was carried
out by polymerase chain reaction (Eppendorf AG. 22331 ham-
burg). Primers were designed on the basis of the sequence data
for APOE. PCR amplifications were performed in a final vol-
ume of 50 ll according to manufacturer’s protocol (Bioflux
PCR Kit) and an optimized PCR reaction was setup (Table 1).
2.4. Restriction fragment length polymorphism (RFLP)
The selected polymorphism (rs121918398) was detected by
restriction analysis, performed on the PCR products, then ana-
lyzed on an agarose gel (1.7%). The substitution of the
8390G>A occurred and caused the conversion of arginine
into histidine amino acid. There are three genotype modes
(AA, AG, GG). A gap in the forward primer was introduced
for distinguishing between the normal and mutant allele by
Hha1 restriction enzyme (Thermo scientific/Catalogue num-
ber: ER1851). The specific restriction enzyme and primers
are summarized in Table 1.
The 89 and 35 bp fragments were obtained in G/G form,
while in the A/G form 124, 89, 35 bp fragments and in the
A/A form, a fragment of 124 bp without cutting site were
obtained (Fig. 1).
Sequencing was performed to confirm PCR-RFLP analysis
results. Sequencing of SNP was carried out by Fazabiotech
Company (Tehran, Iran) according to the Sanger method
using ABI 3730XL Capillary Sequencer. Sequencing results
were compared with the sequence of normal APOE gene
Figure 1 RFLP product. M line is 50 base pair (bp) molecular
marker. In G/G form (3, 4), 89 and 35 bp, in A/G form (2), 124,
89, 35 bp and in A/A form (1), 124 bp fragment without cutting
site were obtained. Because of the smaller size of 35 bp fragments,
it moves through the gel faster and go out of the end, so we
couldn’t indicate the 35 bp band in this figure.
Association of APOE polymorphism with AD and PD 187(NC_000019.10) obtained from the NCBI website: http://
www.ncbi.nlm.nih.gov (Fig. 2).
2.5. Statistical analysis
All statistical analyses were carried out using MedCalc soft-
ware Version 12.7.0.0. In this study the genotype frequencies
of control and patient groups were compared using the chi-
square test. The P-value lower than 0.05 was set as statistically
significant.
3. Results
This study investigated the polymorphism of a SNP loci
8390G>A in APOE gene in 100 AD patients, 100 PD patients
and 150 control volunteers (males and females) using a PCR-
based RFLP analysis. The distribution frequencies of the
SNP loci in AD, PD patients and controls are listed in Table 2.
Most studied participants were females, because the prevalence
of neurodegenerative disease, especially AD, in females is sig-
nificantly higher than males.
3.1. Genotype frequency in healthy volunteers, AD and PD
patients
Among a total of 150 healthy persons, the genotype frequen-
cies were 15, 39 and 96 and in AD patients were 16, 34, 50
(most homozygote E4 genotype were females) and in PD
patients were 14, 32, 54 (most were males) for A/A, A/G and
G/G respectively. The P-value was calculated by MedCalc
software. As a result, no significant difference was observed
in genotype frequencies among genotypes AA, AG, and GG
in healthy, AD and PD patients (P< 0.05), except G/G form
that its prevalence shows a significant difference in the control
group compared with patient group.
3.2. Allele frequency in control, AD and PD patients
In the control group, the frequencies of allele A and allele G
were computed as 23% and 77%, respectively. In addition,
the frequencies of allele A and allele G were 33% and 67%,
among AD patients, in PD patients the frequencies were
30% and 70% respectively. So no significant differences were
observed in allelic frequencies between A and G in healthy
and patient group (Table 2).
4. Discussion
In last decades, neurodegenerative diseases such as Alzhei-
mer’s disease (AD) and Parkinson’s disease (PD), have beenTable 1 PCR primers, annealing temperature, product size and fra
SNP ID Amino acid
change
Primer sequence
rs121918398
(8390G>A)
A292H 50 GAGCAGGCCCAGCAGATACG 3
50 CAGCCTGCACCTTCTCCACC 30paid so much attention due to their high incidence worldwide
[2]. These two disorders have some overlapping clinical and
pathological features [19]. AD is diagnosed by cerebrovascular
and neuronal dysfunctions resulting in a progressive decline in
cognitive functions [20]. This multifactorial disease has some
risk factors among which ‘‘older age” is the strongest one. This
suggests that the biological processes of aging may play an
important role in the pathogenesis of the disease [21]. PD,
the second most prevalent neurodegenerative disorder after
AD, is a neurological disorder. This condition is defined by
the degeneration and progressive loss of neurons in the mid-
brain substantia nigra. This results in a reduction of dopamine
in the striatum [22]. A potential link between APOE and PD
traces back to the role of APOE in lipoprotein metabolism
[8]. Apolipoprotein E (APOE) is a risk factor for Alzheimer’s
disease. It is proposed that it can change the risk of Parkin-
son’s disease although it is considered not to significantly alter
the risk of developing Parkinson’s disease without Parkinson’s
disease dementia.
APOE, mapped on chromosome 19, is well documented as
being a risk factor for the development of late onset Alzhei-
mer’s disease (LOAD) [23,24]. The 3 common APOE moleculegments sizes after restriction treatment for APOE.
PCR
product
size
Restriction
enzyme
Annealing
temp
Mutant
allele
Normal
allele
0 124 bp Hha1 58 124 89, 35
Figure 2 Direct sequencing of the PCR products of APOE gene. Arrow marks the sequence of 8390G>A polymorphisms.
Table 2 The distributions of allele frequencies of SNP
8390G>A in APOE gene in Alzheimer’s and Parkinson
patients and control group.
AA AG GG
AD (100) 16 34 50
Control (150) 15 39 96
P value 0.16 0.17 0.02
Odds ratio 1.71 1.46 1.77
95% CI 0.80–3.64 0.84–2.54 1.06–2.97
PD (100) 14 32 54
Control (150) 15 39 96
P value 0.33 0.3 0.11
Odds ratio 0.68 1.33 1.51
95% CI 0.31–1.48 0.76–2.33 0.90–2.53
188 F. Mohammadpour Lashkari et al.isoforms are encoded by variation in 3 common alleles (e2, e3,
e4). These alleles are specified by 2 single-nucleotide polymor-
phisms (SNPs) in exon 4 of the APOE gene [25]. Among the 88
identified SNPs in the APOE gene, 31 are not synonymous, 8
are coding synonymous, 33 are intronic and 3 are in untrans-
lated region [26].
With regard to the fact that lifespan is increasing, neurode-
generative diseases are becoming of serious concern in these
decades, particularly in developing countries. Accordingly,
we investigated a polymorphism (rs121918398) in the APOE
gene using the PCR-RFLP technique to study the substitution
of arginine amino acid with histidine on codon 292. According
to a previous study [13], rs121918398 polymorphism is consid-
ered to be pathogenic and causing other sorts of diseases than
neurodegenerative ones, but yet there has been no investiga-
tion on this polymorphism and its association with AD or
PD development. In this survey, we investigated the genotype
frequency of 150 healthy persons, 100 AD and 100 PD
patients. The chi-square test result shows no significant differ-
ence between controls, AD and PD patient in homozygous and
heterozygous groups (P< 0.05). Therefore, due to the impact
of APOE4 form on neurodegenerative diseases, this genotype
plays no pathogenic role in the AD and PD. Thus, this poly-
morphism is not considered to be a risk factor for AD and
PD in our studied population.In a different survey, after ethnicity moderating, the e4
allele was found to be significantly associated with earlier
age at onset (P< 0.0001) in the combined group. Among
the Caucasians, the effect of the ApoEe4, on age of onset
was significant (P< 0.0001). This was true for the African
Americans as well (P< 0.05), but not significant in Koreans
(P= 0.43) and in the smaller Hispanic (P= 0.07) group.
The e4 allele was found to be the most frequent one. This study
shows that the impact of APOE polymorphism on age at onset
of AD may vary among different ethnic groups [27].
Another study reports that rs41377151 (located 10.9 kb
away from rs7412 which is one of the coding SNPs for APOE
gene) was significantly associated with LOAD
(P= 3.29  1036) in the T Gen data set [28].
A different study showed that, among the 13 SNPs geno-
typed at <40 kb from the APOE4 polymorphism, 7 (including
APOE4) had evidence of having association with AD
(P 6 0.05) [29].
Moreover, Sando et al. have reported the APOE allele fre-
quencies in 376 AD patients and 561 healthy controls from
central Norway (rs7412 and rs429358). Carriers of the
APOE-e4 allele had an increased OR for developing AD. In
both homozygous and heterozygous individuals, for every
APOE-e4 allele that the patient had, the age of onset in LOAD
patients was significantly lowered (about three years). The
APOE-e2 allele did not affect the age at onset of AD and nei-
ther did this allele have any significant protective effect on the
risk of AD [11].
Results of Multhammer et al. showed no correlation
between combinations of alleles of APOE e3 and APOE e4
in their heterozygote and homozygote forms and prevalence
of PD [30]. Neither did Peplonska et al. demonstrated any sig-
nificant association at the single allele, genotype, or haplotype
levels, concluding that APOE polymorphism is not a risk fac-
tor for Parkinson’s disease in the Polish population [31].
Therefore according to the results of this study, it can be
suggested that 8390G>A SNP of APOE gene plays no role
in developing Alzheimer’s and Parkinson’s disease in Iranian
population. Only G/G genotype illustrates a significant differ-
ence in the control group compared with AD patients
(P= 0.02). It seems that the prevalence of this genotype in
healthy population should be more than in patients. Accord-
Association of APOE polymorphism with AD and PD 189ingly, future investigations on more individuals with AD and
PD could be beneficial.
5. Conclusion
Among various polymorphisms of the APOE gene, some of
which were relevant and/or irrelevant to AD and PD, this
polymorphism (rs121918398) was investigated for the first
time. It should be noted that some other polymorphisms of
the various genes have been investigated in many studies about
AD, PD etc. Since these diseases have multifactorial proper-
ties, broader studies should be conducted, within various races
and generations; all environmental and genetic factors
involved in AD and PD should be accurately studied.
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